Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Sofituzumab vedotin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estrone | Estrone may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estriol | Estriol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Sofituzumab vedotin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Sofituzumab vedotin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sofituzumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Sofituzumab vedotin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Equol | Equol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Sofituzumab vedotin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Sofituzumab vedotin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Sofituzumab vedotin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Sofituzumab vedotin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Sofituzumab vedotin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Sofituzumab vedotin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Sofituzumab vedotin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sofituzumab vedotin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Sofituzumab vedotin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Sofituzumab vedotin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Sofituzumab vedotin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sofituzumab vedotin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sofituzumab vedotin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Sofituzumab vedotin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sofituzumab vedotin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Sofituzumab vedotin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Sofituzumab vedotin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Sofituzumab vedotin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sofituzumab vedotin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sofituzumab vedotin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Sofituzumab vedotin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sofituzumab vedotin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sofituzumab vedotin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Sofituzumab vedotin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sofituzumab vedotin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Sofituzumab vedotin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Sofituzumab vedotin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Sofituzumab vedotin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sofituzumab vedotin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sofituzumab vedotin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Sofituzumab vedotin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Sofituzumab vedotin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Sofituzumab vedotin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Sofituzumab vedotin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Sofituzumab vedotin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Sofituzumab vedotin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Sofituzumab vedotin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Sofituzumab vedotin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Sofituzumab vedotin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Sofituzumab vedotin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Sofituzumab vedotin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Sofituzumab vedotin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Sofituzumab vedotin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Sofituzumab vedotin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Sofituzumab vedotin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Sofituzumab vedotin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Sofituzumab vedotin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Sofituzumab vedotin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Sofituzumab vedotin. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Sofituzumab vedotin. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Sofituzumab vedotin. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Sofituzumab vedotin. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Sofituzumab vedotin. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Sofituzumab vedotin. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Sofituzumab vedotin. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Sofituzumab vedotin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Sofituzumab vedotin. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Sofituzumab vedotin. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Sofituzumab vedotin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Sofituzumab vedotin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Sofituzumab vedotin. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Sofituzumab vedotin. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Sofituzumab vedotin. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sofituzumab vedotin. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Sofituzumab vedotin. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Sofituzumab vedotin. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Sofituzumab vedotin. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Sofituzumab vedotin. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Sofituzumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Sofituzumab vedotin. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Sofituzumab vedotin. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Sofituzumab vedotin. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sofituzumab vedotin. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Sofituzumab vedotin. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Sofituzumab vedotin. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Sofituzumab vedotin. |